|
At issue is the "comparative effectiveness" of various treatments and tests for illnesses and ailments. These winners-and-losers questions drive fierce opposition from drug makers and others who have a financial stake in the outcome. That kind of lobbying has left the nation with a scattershot method for determining best medical practices.
The IOM panel was clear: The new program is not about rationing care -- it doesn't call for insurers to use the results for coverage decisions -- but about finding unbiased information to make the best choices for a given patient. To do that, the research must include typical patients -- usually sicker ones than drug companies enroll in the studies required for sales approval -- the report stressed.
"Patients, even doctors like me, somehow get tongue-tied when it comes time to ask questions of their doctor," Sox said. Eventually, these studies should arm patients with the information to "speak up and really assert themselves in talking with their doctor, to be sure their preferences are reflected in whatever treatment or testing is eventually decided on."
The report didn't put a price tag on the called-for studies, but that $1.1 billion will cover only a fraction of the projects. Nor is it clear how quickly the answers will arrive.
But Obama administration officials have stressed that quickly disseminating the research results also will be a priority, so the data translates into better care.
[Associated
Press;
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor